GlassScriptPhysician profile
Shashank Jain
NPI 1174865653
$14,377.00
in general payments reported to CMS, 2019-2025
14 companies · $2,200 in 2025
The $2,200 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,715 · 2020: $1,234 · 2021: $261 · 2022: $967 · 2023: $3,379 · 2024: $621 · 2025: $2,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,075 · Travel and Lodging: $2,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,074.64 |
| Travel and Lodging | $2,125.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,997.20 | 2019-2025 | Watchman Access System, Farapulse, Sq-Rx Pulse Generator |
| Medtronic, INC. | $3,704.20 | 2021-2025 | Micra, Hawkone, Pulseselect |
| Medtronic Vascular, INC. | $3,483.66 | 2019 | |
| Abbott Laboratories | $2,799.52 | 2021-2025 | Aveir, Ensite, Advisor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.94 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $69.38 | 2024-2025 | Eliquis, Camzyos |
| Cardiva Medical, INC. | $49.84 | 2019 | |
| Amgen INC. | $47.99 | 2021-2022 | |
| Atricure, INC. | $22.40 | 2019 | |
| Esperion Therapeutics, INC. | $21.12 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $20.14 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.98 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.00 | 2024 | Jardiance |
| Pfizer INC. | $13.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashank Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.